{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:30Z","timestamp":1782337230791,"version":"3.54.5"},"reference-count":175,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) represent a complex interplay between autoimmune and fibrotic processes that poses significant diagnostic and therapeutic challenges. The distinction between isolated ANCA-ILD and AAV-ILD remains a subject of ongoing debate, with some researchers proposing that ANCA-ILD may be an early or restricted form of systemic vasculitis. Immunosuppressive therapy is the cornerstone of treatment for both diseases. However, there is increasing evidence that supports the potential role of antifibrotic agents in the management of progressive fibrosis. Management of these diseases requires a personalized approach that incorporates evaluation of biomarkers, imaging findings, and clinical risk factors to guide treatment decisions. Although current therapeutic strategies primarily target systemic inflammation, addressing the fibrotic components of these diseases is crucial for improving outcomes. Furthermore, emerging therapeutic options, such as B-cell depletion and antifibrotic therapies, offer promising outcomes. However, their roles in the treatment of AAV-ILD require further exploration. In this review, we discuss clinical insights and evolving therapeutic strategies for managing AAV and ANCA-positive ILD. In addition, we highlight the importance of early diagnosis and individualized treatment plans in improving the prognosis and quality of life of affected patients.<\/jats:p>","DOI":"10.3390\/jcm14134631","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:06:17Z","timestamp":1751288777000},"page":"4631","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Insights and Therapeutic Strategies for the Treatment of Interstitial Lung Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Trends and Future Directions"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9135-1580","authenticated-orcid":false,"given":"Justyna","family":"Fijolek","sequence":"first","affiliation":[{"name":"Third Department of Pneumonology and Oncology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sniady","sequence":"additional","affiliation":[{"name":"Medical Academy of Applied Holistic Sciences, 01-234 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/art.21250","article-title":"Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome","volume":"52","author":"Sinico","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","article-title":"Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome","volume":"143","author":"Cohen","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/mr\/road001","article-title":"Evaluation of prognostic factors for patients with eosinophilic granulomatosis and polyangiitis recruited at the pneumonological centre and mainly ANCA negativity: A retrospective analysis of a single cohort in Poland","volume":"34","author":"Fijolek","year":"2023","journal-title":"Modern Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fijolek, J., and Radzikowska, E. (2023). Eosinophilic granulomatosis with polyangiitis\u2014Advances in pathogenesis, diagnosis, and treatment. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1145257"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Potentas-Policewicz, M., and Fijolek, J. (2024). Granulomatosis with polyangiitis: Clinical characteristics and updates in diagnosis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1369233"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.2024.3669","article-title":"Interstitial lung disease","volume":"331","author":"Maher","year":"2024","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0025-6196(12)62575-0","article-title":"Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients","volume":"65","author":"Nada","year":"1990","journal-title":"Mayo Clin. Proc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.rmed.2008.04.023","article-title":"ANCA-associated lung fibrosis: Analysis of 17 patients","volume":"102","author":"Foulon","year":"2008","journal-title":"Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000183754","article-title":"A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients","volume":"77","author":"Nozu","year":"2009","journal-title":"Respiration"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"210123","DOI":"10.1183\/16000617.0123-2021","article-title":"Antineutrophil cytoplasmic antibody-associated interstitial lung disease: A review","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100235","DOI":"10.1016\/j.jtauto.2024.100235","article-title":"Presentation and progression of MPO-ANCA interstitial lung disease","volume":"8","author":"Salvati","year":"2024","journal-title":"J. Transl. Autoimmun."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"WGET Research Group (2002). Design of the Wegener\u2019s Granulomatosis Etanercept Trial (WGET). Control. Clin. Trials, 23, 450\u2013468.","DOI":"10.1016\/S0197-2456(02)00209-X"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1479973121994562","DOI":"10.1177\/1479973121994562","article-title":"Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: A systematic literature review and meta-analysis","volume":"18","author":"Zhou","year":"2021","journal-title":"Chronic Respir. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/rheumatology\/kem107","article-title":"Prevalence of Wegener\u2019s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden","volume":"46","author":"Mohammad","year":"2007","journal-title":"Rheumatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.40313","article-title":"Epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota","volume":"69","author":"Berti","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2214\/AJR.18.20967","article-title":"Chest High-Resolution CT findings of microscopic polyangiitis: A Japanese first nationwide prospective cohort study","volume":"213","author":"Suzuki","year":"2019","journal-title":"Am. J. Roentgenol."},{"key":"ref_22","first-page":"S221","article-title":"Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis","volume":"38","author":"Sebastiani","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/keac339","article-title":"Interstitial lung disease in ANCA-associated vasculitis: Associated factors, radiographic features and mortality","volume":"62","author":"Doliner","year":"2023","journal-title":"Rheumatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1183\/09031936.00110109","article-title":"Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis","volume":"36","author":"Tzelepis","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/rheumatology\/ker236","article-title":"Interstitial lung disease and ANCA-associated vasculitis: A retrospective observational cohort study","volume":"50","author":"Arulkumaran","year":"2011","journal-title":"Rheumatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s00296-011-2079-4","article-title":"Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea","volume":"32","author":"Ahn","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Huang, H., Wang, Y.X., Jiang, C.G., Liu, J., Xu, K., and Xu, Z.J. (2014). A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China. BMC Pulm. Med., 14.","DOI":"10.1186\/1471-2466-14-8"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10067-014-2676-1","article-title":"Microscopic polyangiitis associated with pulmonary fibrosis","volume":"34","author":"Casarez","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00296-014-3106-z","article-title":"Characteristics of MPO-ANCA-positive granulomatosis with polyangiitis: A retrospective multi-center study in Japan","volume":"35","author":"Ono","year":"2015","journal-title":"Rheumatol. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/rheumatology\/keab325","article-title":"Pulmonary involvement in primary systemic vasculitides","volume":"61","author":"Makhzoum","year":"2022","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Potentas-Policewicz, M., Gawryluk, D., Wiatr, E., and Fijolek, J. (2025). Age-related variations in the clinical presentation and treatment outcomes of new-onset GPA: A longitudinal study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14051544"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11926-022-01078-2","article-title":"Interstitial lung disease in ANCA-associated vasculitis: Pathogenic considerations and impact for patients\u2019 outcomes","volume":"24","author":"Sun","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00408-016-9851-x","article-title":"Clinical implication of proteinase-3\u2014Antineutrophil cytoplasmic antibody in patients with idiopathic interstitial pneumonias","volume":"194","author":"Hozumi","year":"2016","journal-title":"Lung"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.rmed.2013.01.006","article-title":"Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangiitis in the course of idiopathic pulmonary fibrosis","volume":"107","author":"Ando","year":"2013","journal-title":"Respir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e000058","DOI":"10.1136\/bmjresp-2014-000058","article-title":"Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis","volume":"2","author":"Kagiyama","year":"2015","journal-title":"BMJ Open Resp. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.chest.2019.05.014","article-title":"Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in North American patients with idiopathic pulmonary fibrosis","volume":"156","author":"Liu","year":"2019","journal-title":"Chest"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"i83","DOI":"10.1093\/ndt\/gfu385","article-title":"Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan","volume":"30","author":"Hirayama","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MD.0b013e31817c744b","article-title":"Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients","volume":"87","author":"Chen","year":"2008","journal-title":"Medicine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s10067-015-2967-1","article-title":"Reduced survival in microscopic polyangiitis patients with pulmonary fibrosis in a respiratory referral centre","volume":"34","author":"Ruiz","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kono, M., Nakamura, Y., Enomoto, N., Hashimoto, D., Fujisawa, T., Inui, N., Maekawa, M., Suda, T., Colby, T.V., and Chida, K. (2014). Usual interstitial pneumonia preceding collagen vascular disease: A retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094775"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ajcp\/104.1.7","article-title":"The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase","volume":"104","author":"Gaudin","year":"1995","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MD.0000000000000217","article-title":"Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. A series of 49 patients and review of the literature","volume":"93","author":"Comarmond","year":"2014","journal-title":"Medicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.autrev.2017.05.008","article-title":"Interstitial lung disease in ANCA vasculitis","volume":"16","author":"Alba","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Valero-Martinez, C., Valenzuela, C., Acha, J.P.B., Martinez-Besteiro, E., Quiroga-Colina, P., Alfranca, A., Vicente-Rabaneda, E.F., Muniz, S.H., Castaneda, S., and Garcia-Vicuna, R. (2025). Clinical profiles, survival, and lung function outcomes in ANCA-associated interstitial lung disease: An observational study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14010229"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102467","DOI":"10.1016\/j.jaut.2020.102467","article-title":"Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry","volume":"112","author":"Ngyuen","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","article-title":"Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Rheumatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.3899\/jrheum.160005","article-title":"Comparison of the phenotype and outcome of granulomatosis with polyangiitis between UK and Japanese cohort","volume":"44","author":"Furuta","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1183\/09031936.00148409","article-title":"The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis","volume":"37","author":"Guilpain","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/path.4359","article-title":"Neutrophil extracellular traps promote differentiation and function of fibroblasts","volume":"233","author":"Chrysanthopoulou","year":"2014","journal-title":"J. Pathol."},{"key":"ref_50","first-page":"e300","article-title":"Myeloperoxidase-specific antineutrophil cytoplasmic antibody-associated vasculitis","volume":"6","author":"Arnold","year":"2024","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00000478-199104000-00001","article-title":"Surgical pathology of the lung in Wegener\u2019s granulomatosis. Review of 87 open lung biopsies from 67 patients","volume":"15","author":"Travis","year":"1991","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/annrheumdis-2018-214263","article-title":"Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"78","author":"Namba","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13075-020-02347-0","article-title":"Association of TERT and DSP variants with microscopic polyangiitis and myeloperoxidase-ANCA positive vasculitis in a Japanese population: A genetic association study","volume":"22","author":"Kawasaki","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"102338","DOI":"10.1016\/j.jaut.2019.102338","article-title":"Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor","volume":"106","author":"Maillet","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1055\/s-0038-1669914","article-title":"Antineutrophil cytoplasmic antibody-associated lung fibrosis","volume":"39","author":"Borie","year":"2018","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"102618","DOI":"10.1016\/j.autrev.2020.102618","article-title":"2020 international consensus on ANCA testing beyond systemic vasculitis","volume":"19","author":"Moiseev","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e5096","DOI":"10.1097\/MD.0000000000005096","article-title":"Diagnosing ANCA-associated vasculitis in ANCA positive patients: A retrospective analysis on the role of clinical symptoms and the ANCA titre","volume":"95","author":"Houben","year":"2016","journal-title":"Medicine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s10067-025-07412-0","article-title":"Serum ferritin is a superior biomarker for evaluating disease activity and kidney injury compared with C-reactive protein in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"44","author":"Xie","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Conticini, E., d\u2019Alessandro, M., Bergantini, L., Castillo, D., Cameli, P., Frediani, B., Cantarini, L., and Bargagli, E. (2022). KL-6 in ANCA-associated vasculitis patients with and without ILD: A machine learning approach. Biology, 11.","DOI":"10.3390\/biology11010094"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/03009742.2022.2045790","article-title":"Pentraxin-3\u2014A potential biomarker in ANCA-associated vasculitis","volume":"52","author":"Jonasdottir","year":"2023","journal-title":"Scand. J. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13075-025-03503-0","article-title":"Association of C4d with disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis: Evidence for classical\/lectin complement pathway activation","volume":"27","author":"Juto","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"ref_66","first-page":"e2024025","article-title":"Pulmonary function in patients with ANCA-associated vasculitis","volume":"41","author":"Dieterich","year":"2024","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1164\/rccm.202308-1426OC","article-title":"and PEXIVAS Investigators. Alveolar hemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: Results of an international randomized controlled trial (PEXIVAS)","volume":"209","author":"Fussner","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/RHU.0000000000001357","article-title":"Interstitial lung disease in antineutrophil cytoplasmic antibody-associated vasculitis patients: Comparison with idiopathic pulmonary fibrosis","volume":"27","author":"Kwon","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"ref_69","first-page":"PA1362","article-title":"Interstitial lung disease associated with ANCA positivity: A retrospective analysis","volume":"54","author":"Juman","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.161224","article-title":"Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)\u2014Associated vasculitis: The influence of ANCA subtype","volume":"44","author":"Mohammad","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_71","first-page":"195","article-title":"Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: A retrospective analysis","volume":"36","author":"Baqir","year":"2019","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"152726","DOI":"10.1016\/j.semarthrit.2025.152726","article-title":"Interstitial lung disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis: Chest CT patterns and correlation with survival","volume":"73","author":"Tandon","year":"2025","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000529085","article-title":"Patterns of interstitial lung disease and prognosis in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"102","author":"Zhou","year":"2023","journal-title":"Respiration"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"105797","DOI":"10.1016\/j.ijmedinf.2025.105797","article-title":"Identification of an ANCA-associated vasculitis cohort using deep learning and electronic health records","volume":"196","author":"Wang","year":"2025","journal-title":"Int. J. Med. Inf."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Bermejo-Pel\u00e1ez, D., Ash, S.Y., Washko, G.R., San Jos\u00e9 Est\u00e9par, R., and Ledesma-Carbayo, M.J. (2020). Classification of interstitial lung abnormality patterns with an ensemble of deep convolutional neural networks. Sci. Rep., 10.","DOI":"10.1038\/s41598-019-56989-5"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Lami, K., Ozasa, M., Che, X., Uegami, W., Kato, Y., Zaizen, Y., Tsuyama, N., Mori, I., Ichihara, S., and Yoon, H. (2025). Enhancing interstitial lung disease diagnoses through multimodal AI integration of histopathological and CT image data. Respirology.","DOI":"10.1111\/resp.70036"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/resp.12763","article-title":"Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis","volume":"21","author":"Hosoda","year":"2016","journal-title":"Respirology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40674-019-00127-9","article-title":"Interstitial lung disease and ANCA-associated vasculitis","volume":"5","author":"Sacoto","year":"2019","journal-title":"Curr. Treat. Options Rheum."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.athoracsur.2017.02.013","article-title":"Mortality and respiratory failure after thoracoscopic lung biopsy for interstitial lung disease","volume":"104","author":"Durheim","year":"2017","journal-title":"Ann. Thorac. Surg."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2213-2600(19)30342-X","article-title":"Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): A prospective, comparative study","volume":"8","author":"Troy","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1843.2004.00581.x","article-title":"Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides","volume":"9","author":"Homma","year":"2004","journal-title":"Respirology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.rmed.2012.08.024","article-title":"Interstitial pneumonia associated with MPO-ANCA: Clinicopathological features of nine patients","volume":"106","author":"Tanaka","year":"2012","journal-title":"Respir. Med."},{"key":"ref_83","first-page":"821","article-title":"Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: Demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology","volume":"41","author":"Manfredi","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10067-021-05964-5","article-title":"Patterns of lung diseases predict survival in patients with MPO-ANCA-associated vasculitis: A single-center retrospective study","volume":"41","author":"Yang","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Matsuda, S., Kotani, T., Suzuka, T., Kiboshi, T., Fukui, K., Wakama, M., Ishida, T., Fujiki, Y., Shiba, H., and Nagai, K. (2021). Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-81311-7"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zhou, P., Li, Z., Gao, L., Que, C., Li, H., Ma, J., Wang, G., and Chen, M. (2022). Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-022-01829-y"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s10067-025-07378-z","article-title":"Risk factors for poor prognosis in ANCA-associated vasculitis with interstitial lung disease: A systematic review and meta-analysis","volume":"44","author":"He","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_88","unstructured":"Castellino, J., Orentas, M., Moran, J., Fair, J., Zhang, Y., and Bukiej, A. (2024). Interstitial lung disease in ANCA-associated vasculitis: A retrospective study of clinical characteristics, radiographic features, and outcomes [abstract]. Arthritis Rheumatol., 76, Available online: https:\/\/acrabstracts.org\/abstract\/interstitial-lung-disease-in-anca-associated-vasculitis-a-retrospective-study-of-clinical-characteristics-radiographic-features-and-outcomes\/."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Libra, A., Muscato, G., Ielo, G., Spicuzza, L., Palmucci, S., Fagone, E., Fruciano, M., Gili, E., Sambataro, G., and Vancheri, C. (2023). Clinical and prognostic significance of p-ANCA positivity in idiopathic pulmonary fibrosis: A retrospective observational study. Diagnostics, 13.","DOI":"10.3390\/diagnostics13111882"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"152648","DOI":"10.1016\/j.semarthrit.2025.152648","article-title":"ANCA-associated vasculitis in patients with rheumatoid arthritis: A single-center cohort study","volume":"71","author":"Bolotin","year":"2025","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Wu, T., Cao, C., Cen, Z., Zhou, H., Lv, D., Zhang, Y., and Ding, Q. (2025). Prevalence and clinical significance of anti-neutrophil cytoplasmic antibodies in interstitial lung disease: A retrospective cohort study. Rheumatology.","DOI":"10.1093\/rheumatology\/keaf108"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.resinv.2024.11.006","article-title":"Clinical characteristics and prognostic factors for MPO-ANCA positive interstitial lung disease: A comparative study of ANCA associated vasculitis (AA)\u2014ILD and pulmonary limited vasculitis","volume":"63","author":"Shimamura","year":"2025","journal-title":"Respir. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/acr2.11679","article-title":"Comparison of interstitial lung disease between antineutrophil cytoplasmic antibodies positive and negative patients: A retrospective cohort study","volume":"6","author":"Shen","year":"2024","journal-title":"ACR Open Rheumatol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Sakamoto, S., Suzuki, A., Homma, S., Usui, Y., Shimizu, H., Sekiya, M., Miyoshi, S., Nakamura, Y., Urabe, N., and Isshiki, T. (2023). Outcomes and prognosis of progressive pulmonary fibrosis in patients with antineutrophil cytoplasmic antibody-positive interstitial lung disease. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-45027-0"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"On behalf of the ERS\/ATS Task Force on Undifferentiated Forms of CTD-ILD. An official European Respiratory Society\/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_96","first-page":"101111","article-title":"Interstitial lung diseases associated with ANCA positivity: A different disease spectrum from interstitial pneumonia with autoimmune features","volume":"86","author":"Zhu","year":"2024","journal-title":"Respir. Med. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_98","first-page":"e2021015","article-title":"Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease","volume":"38","author":"Fidler","year":"2021","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ccm.2019.05.012","article-title":"Update on the management of respiratory manifestations of the antineutrophil cytoplasmic antibodies-associated vasculitides","volume":"40","author":"Thompson","year":"2019","journal-title":"Clin. Chest Med."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu, G., Anstrom, K.J., King, T.E., Lasky, J.A., and Martinez, F.J. (2012). Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med., 366, 1968\u20131977.","DOI":"10.1056\/NEJMoa1113354"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1164\/rccm.202401-0048PP","article-title":"The role of inflammation and fibrosis in interstitial lung disease treatment decisions","volume":"210","author":"Behr","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Yamakawa, H., Toyoda, Y., Baba, T., Kishaba, T., Fukuda, T., Takemura, T., and Kuwano, K. (2022). Anti-inflammatory and\/or anti-fibrotic treatment of MPO-ANCA-positive interstitial lung disease: A short review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133835"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00408-022-00532-3","article-title":"Serum oncomarkers in patients with MPO-ANCA-positive vasculitis: Diagnostic and prognostic predictive values for interstitial lung disease","volume":"200","author":"Yang","year":"2022","journal-title":"Lung"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41584-021-00721-z","article-title":"Acute exacerbation of interstitial lung disease associated with rheumatic disease","volume":"18","author":"Luppi","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_107","first-page":"147","article-title":"Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement","volume":"4","author":"Fisher","year":"2020","journal-title":"Can. J. Respir. Crit. Care Sleep Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.202305-0796OC","article-title":"Combination of BAL and computed tomography differentiates progressive and non-progressive fibrotic lung diseases","volume":"208","author":"Barnett","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"240194","DOI":"10.1183\/16000617.0194-2024","article-title":"A systematic review of the role of quantitative CT in the prognostication and disease monitoring of interstitial lung disease","volume":"34","author":"Dixon","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1093\/ndt\/gfab357","article-title":"Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: A systematic review and meta-analysis","volume":"37","author":"Berti","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2204449","DOI":"10.1080\/07853890.2023.2204449","article-title":"Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: Probability of preexisting comorbidities","volume":"55","author":"Zhang","year":"2023","journal-title":"Ann. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2103187","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: An expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Liossis, S.N.C., and Bounia1, C.A. (2022). Treating autoimmune-related interstitial lung disease with B cell depletion. Front. Med., 9.","DOI":"10.3389\/fmed.2022.937561"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12931-022-02082-x","article-title":"Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: A systematic review and meta-analysis","volume":"23","author":"Zhao","year":"2022","journal-title":"Respir. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): A double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): A double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_124","first-page":"101144","article-title":"Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial","volume":"87","author":"Ferreira","year":"2024","journal-title":"Respir. Med. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS\u00ae trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: A systematic review and meta-analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: Pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: A randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/thorax-2022-219795","article-title":"Pirfenidone in fibrotic hypersensitivity pneumonitis: A double-blind, randomised clinical trial of efficacy and safety","volume":"78","author":"Crooks","year":"2023","journal-title":"Thorax"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Ushio, Y., Wakiya, R., Kameda, T., Nakashima, S., Shimada, H., Miyagi, T., Sugihara, K., Mino, R., Mizusaki, M., and Chujo, K. (2024). Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: A single-center study. BMC Rheumatol., 8.","DOI":"10.1186\/s41927-024-00400-y"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"00084","DOI":"10.1183\/23120541.00084-2018","article-title":"Long-term safety of pirfenidone: Results of the prospective, observational PASSPORT study","volume":"4","author":"Cottin","year":"2018","journal-title":"ERJ Open Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"A3027","DOI":"10.1016\/j.chest.2023.07.1984","article-title":"Combination therapy with pirfenidone and nintedanib in idiopathic pulmonary fibrosis: A systematic review and meta-analysis","volume":"164","author":"Gandhi","year":"2023","journal-title":"Chest"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"240015","DOI":"10.1183\/16000617.0015-2024","article-title":"Lysophosphatidic acid receptor 1 inhibition: A potential treatment target for pulmonary fibrosis","volume":"33","author":"Volkmann","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","article-title":"Efficacy and safety of Admilparant, an LPA1 antagonist, in pulmonary fibrosis: A phase 2 randomized clinical trial","volume":"211","author":"Corte","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1111\/bph.17303","article-title":"PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells","volume":"181","author":"Reininger","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"and 1305-0013 Trial Investigators. Trial of a preferential Phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e001563","DOI":"10.1136\/bmjresp-2022-001563","article-title":"Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)","volume":"10","author":"Richeldi","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e001580","DOI":"10.1136\/bmjresp-2022-001580","article-title":"Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)","volume":"10","author":"Maher","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis","volume":"392","author":"Richeldi","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/thorax-2022-219391","article-title":"Inhaled pirfenidone solution (AP01) for IPF: A randomised, open-label, dose-response trial","volume":"78","author":"West","year":"2023","journal-title":"Thorax"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.33590\/emjrespir\/MXJY9650","article-title":"Inhalation innovation: Phase IIb study design of inhaled pirfenidone in the treatment of progressive pulmonary fibrosis","volume":"12","author":"Kolb","year":"2024","journal-title":"EMJ Respir."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"101933","DOI":"10.1016\/j.pupt.2020.101933","article-title":"Inhalation: A means to explore and optimize nintedanib\u2019s pharmacokinetic\/pharmacodynamic relationship","volume":"63","author":"Pham","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"101938","DOI":"10.1016\/j.pupt.2020.101938","article-title":"Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis","volume":"63","author":"Surber","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"105615","DOI":"10.1016\/j.jddst.2024.105615","article-title":"Inhaled nintedanib nanoparticles for enhanced efficacy in idiopathic pulmonary fibrosis (IPF) treatment\u2014Evidence in disease-relevant in-vitro models","volume":"95","author":"Wang","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled Treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e001310","DOI":"10.1136\/bmjresp-2022-001310","article-title":"Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Respir. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"100124","DOI":"10.1016\/j.chpulm.2024.100124","article-title":"Study design and rationale for the TETON-PPF Phase 3, randomized, controlled clinical trial of inhaled Treprostinil in the treatment of progressive pulmonary fibrosis","volume":"3","author":"Nathan","year":"2025","journal-title":"Chest Pulm."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"D\u2019Agnano, V., Perrotta, F., Fomez, R., Carrozzo, V.M., Schiatarella, A., Zamparelli, S.S., Pagliaro, R., Bianco, A., and Mariniello, D.F. (2024). Pharmacological treatment of interstitial lung diseases: A novel landscape for inhaled agents. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16111391"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2147\/DDDT.S353494","article-title":"Therapeutic potential of Janus kinase inhibitors for the management of interstitial lung disease","volume":"16","author":"Huo","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12931-018-0728-9","article-title":"The JAK2 pathway is activated in idiopathic pulmonary fibrosis","volume":"19","author":"Milara","year":"2018","journal-title":"Respir. Res."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Venerito, V., Manfredi, A., Carletto, A., Gentileschi, S., Atzeni, F., Guiducci, S., Lavista, M., La Corte, L., Pedrollo, E., and Scardapane, A. (2023). Evolution of rheumatoid-arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: A retrospective exploratory study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030957"},{"key":"ref_156","first-page":"2071","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data","volume":"40","author":"Kalyoncu","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"103636","DOI":"10.1016\/j.autrev.2024.103636","article-title":"Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis","volume":"23","author":"Nolla","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/annrheumdis-2021-220484","article-title":"Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: A pilot study","volume":"80","author":"Liu","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3899\/jrheum.221219","article-title":"Response to treatment with Tofacitinib in 11 patients with refractory granulomatosis with polyangiitis","volume":"50","author":"Linde","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Perrotta, F., Zamparelli, S.S., D\u2019Agnano, V., Montella, A., Fomez, R., Pagliaro, R., Schiatarella, A., Cazzola, M., Bianxco, A., and Marinello, D.F. (2024). Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071384"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(14)70124-9","article-title":"Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: An observational cohort study with independent validation","volume":"2","author":"Stuart","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S2213-2600(17)30216-3","article-title":"The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: An observational cohort-control study","volume":"5","author":"Ley","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e002935","DOI":"10.1136\/rmdopen-2022-002935","article-title":"Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism","volume":"9","author":"Moura","year":"2023","journal-title":"RMD Open"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Kawasaki, A., Sada, K.E., Kusumawati, P.A., Hirano, F., Kobayashi, S., Nagasaka, K., Sugihara, T., Ono, N., Fujimoto, T., and Kusaoi, M. (2023). Association of HLA-class II alleles with risk of relapse in myeloperoxidase-antineutrophil cytoplasmic antibody positive vasculitis in the Japanese population. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1119064"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12931-025-03139-3","article-title":"Supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States","volume":"26","author":"Yang","year":"2025","journal-title":"Respir. Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1900421","DOI":"10.1183\/13993003.00421-2019","article-title":"Oxygen in patients with fibrotic interstitial lung disease: An international Delphi survey","volume":"54","author":"Lim","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): A prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Choi, H.E., Kim, T.H., Jang, J.H., Jang, H.J., Yi, J., Jung, S.Y., Kim, D.W., and Lee, J.H. (2023). The Efficacy of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Life, 13.","DOI":"10.3390\/life13020403"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"106473","DOI":"10.1016\/j.rmed.2021.106473","article-title":"Pulmonary rehabilitation in patients with interstitial lung diseases: Correlates of success","volume":"185","author":"Brunetti","year":"2021","journal-title":"Respir. Med."},{"key":"ref_170","unstructured":"Terrier, B., Richert, L., Pugnet, G., Aumaitre, O., Moranne, O., Diot, E., Karras, A., Bonnet, F., De Moreuil, C., and Hachulla, E. (2022). Innovative anti-pneumococcal vaccine strategies versus standard vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A multicenter randomized controlled trial (PNEUMOVAS) [abstract]. Arthritis Rheumatol., 74, Available online: https:\/\/acrabstracts.org\/abstract\/innovative-anti-pneumococcal-vaccine-strategies-versus-standard-vaccination-regimen-in-patients-with-anca-associated-vasculitides-receiving-rituximab-therapy-a-multicenter-randomized-controlled-trial\/."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Lim, C.Y., Khan, S.W., Alsibai, T., and Sathiyamoorthy, G. (2025). Examining cough\u2019s role and relief strategies in interstitial lung disease. J. Clin. Med., 14.","DOI":"10.3390\/jcm14010291"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"00423","DOI":"10.1183\/23120541.00423-2022","article-title":"Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study","volume":"9","author":"Raman","year":"2023","journal-title":"ERJ Open Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2300752","DOI":"10.1183\/13993003.00752-2023","article-title":"and INBUILD Trial Investigators. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis","volume":"63","author":"Wijsenbeek","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/MCP.0000000000000979","article-title":"Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis: An update on pathogenesis and treatment","volume":"29","author":"Turgeon","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation","volume":"40","author":"Leard","year":"2021","journal-title":"J. Heart Lung Transplant."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4631\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:57Z","timestamp":1760032917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":175,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14134631"],"URL":"https:\/\/doi.org\/10.3390\/jcm14134631","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}